Utah’s Biomerics Announces Expansion of Texas, Costa Rica Operations
March 11, 2021
Biomerics, headquartered in Salt Lake City, and a leading mid-market medical device contract manufacturer, has announced it is expanding its manufacturing footprint in Athens, TX where Biomerics FMI is a vertically integrated high volume catheter development and manufacturing leader in the attractive PTA, Endourology, and Endoscopy markets.
The Texas expansion totals 24,000 sq. ft. including professional office space, engineering labs, quality inspection labs, 10,000 sq. ft. class 8 clean room, and machining center. Biomerics FMI currently employs 420 people at its 80,000 sq. ft. five facility campus, a center of excellence in extrusion, injection molding, medical balloon forming, advanced shaft reflow, coating, catheter assembly, packaging, and sterilization.
“We are excited to expand our footprint in Athens, Texas,” stated Travis Sessions, Biomerics CEO. “Biomerics FMI has storied history in this community and we look forward to continuing this legacy.”
Biomerics has also announced that it is doubling its manufacturing footprint in the La Zeta Free Trade Zone in Cartago, Costa Rica. Biomerics held a joint groundbreaking ceremony with La Zeta and CINDE on Friday, February 12, 2021.
The expansion is via a new greenfield plant adjacent to Biomerics current operations and includes extrusion, injection molding, micro metal processing, and cleanroom assembly process. The new facility construction totaling 110,000 sq. ft. will reflect Biomerics vertically integrated, full-service business model and will include engineering labs, quality inspection labs, controlled environment manufacturing, office space, class 7 clean rooms, packaging, and warehouse facilities.
Biomerics currently employs 175 people at its 50,000 sq. ft. facility focused on extrusion, laser processing, high volume assembly, and packaging.
“This expansion is in line with our vision to be the leading interventional contract manufacturer,” stated Travis Sessions, Biomerics CEO. “Customers have requested that we build a vertically integrated operation in Costa Rica to provide cost-effective high volume manufacturing for the interventional market.”
Construction is expected to be completed by Q4 2021 and will be celebrated with an open house.